

Supporting Information

KI- catalyzed reaction of aryl hydrazines with α -oxocarboxylic acids in the presence of CO₂: access to 1,3,4-oxadiazol-2(3H)-ones

Na Yang, Hao Zhang and Gaoqing Yuan*

Key Laboratory of Functional Molecular Engineering of Guangdong Province, School of
Chemistry and Chemical Engineering, South China University of Technology
Guangzhou 510640, China
E-mail: gqyuan@scut.edu.cn

List of contents

1. General methods	S2
2. General procedure for the synthesis of 1,3,4-oxadiazol-2(3H)-one.....	S2
3. General procedure for α -oxocarboxylic acids.....	S2
4. Characterization data	S3
5. Reference	S11
6. NMR spectra	S12

1. General methods

¹H and ¹³C NMR spectra were recorded by using a Bruker DRX-400 spectrometer and CDCl₃ as the solvent. The chemical shifts were referenced to signals at 7.26 and 77.23 ppm, respectively. Mass spectra were recorded on a Thermo Scientific ISQ gas chromatograph-mass spectrometer. The data of HRMS were obtained on a high resolution mass spectrometer (LCMS-IT-TOF). Melting points were determined with a Büchi Melting Point B-545 instrument.


2. General procedure for the synthesis of 1,3,4-oxadiazol-2(3H)-one

In a typical procedure, phenylhydrazine **1a** (0.5 mmol), 2-oxo-2-phenylacetic acid **2a** (0.5 mmol), KI (0.2 equiv.), TBHP (4.0 equiv. 70% in water) and K₂CO₃ (2 equiv.) were dissolved in 5 mL MeOH in a dried 15 mL polytetrafluoroethylene (PTFE) reaction vessel. The vessel was fixed into a stainless-steel autoclave with a pressure regulating system. Then the autoclave was sealed and CO₂ was introduced from a cylinder. The reaction was carried out at the selected temperature under magnetic stirring for 4.5 h and the pressure was kept constant during the reaction. After the reaction was completed, the vessel was cooled and the pressure was released slowly to atmospheric pressure. Then reaction mixture was diluted with H₂O (20 mL) and extracted with EtOAc (15 mL×3). The combined organic layer was dried over anhydrous MgSO₄ and then filtered. The solvent was removed under vacuo and the crude product was separated by column chromatography on a silica gel column using petroleum ether/ethyl acetate as eluent to give the desired product **3** or **4**.

3. General procedure for α -oxocarboxylic acids¹

The substituted α -oxocarboxylic acids (**2a–2j**) were prepared by oxidation of corresponding methyl ketones with SeO₂ (Scheme S1). Methyl ketones (5 mmol), SeO₂ (6 mmol), 20 mL of pyridine were added in a 50 mL round-bottom flask. The reaction mixture was stirred at 110 °C for 1 h, then reduce the temperature to 90 °C for 4 h. The desired products (**2a–2j**) were isolated by silica-gel column chromatography


in excellent yields (65–90%).



Scheme S1 Preparation of α -oxocarboxylic acids.


4. Characterization data

3,5-diphenyl-1,3,4-oxadiazol-2(3H)-one (3a)²




White solid, mp 109–110 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.83 (t, J = 7.4 Hz, 4H), 7.42 – 7.33 (m, 5H), 7.16 (t, J = 7.4 Hz, 1H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 153.7, 150.8, 136.2, 132.1, 129.3, 129.2, 126.3, 126.1, 123.6, 118.4.

3-(4-fluorophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3b)²




White solid, mp 148–150 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.92 (td, J = 6.8, 3.1 Hz, 4H), 7.55 – 7.49 (m, 3H), 7.18 – 7.13 (m, 2H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 160.8 (d, J = 244.7 Hz), 153.8, 150.9, 132.4 (d, J = 2.8 Hz), 132.3, 129.3, 126.2, 123.5, 120.4 (d, J = 8.2 Hz), 116.2 (d, J = 22.8 Hz).

3-(4-chlorophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3c)²




White solid, mp 143–145 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.91 (t, J = 8.3 Hz, 4H), 7.55 – 7.48 (m, 3H), 7.42 (d, J = 8.9 Hz, 2H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 153.9, 150.6, 134.8, 132.3, 131.7, 129.5, 129.3, 126.2, 123.4, 119.6.

3-(4-bromophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3d)³




White solid, mp 135–137 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.91 (d, *J* = 7.1 Hz, 2H), 7.83 (d, *J* = 8.9 Hz, 2H), 7.56 – 7.47 (m, 5H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 153.9, 150.5, 135.3, 132.4, 132.3, 129.3, 126.2, 123.4, 119.8, 119.4.

5-phenyl-3-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2(3H)-one (3e)




White solid, mp 111–113 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 8.05 (d, *J* = 8.4 Hz, 2H), 7.89 (d, *J* = 7.1 Hz, 2H), 7.67 (d, *J* = 8.5 Hz, 2H), 7.55 – 7.45 (m, 3H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 154.1, 150.4, 138.9, 132.4, 129.3 (q, *J* = 87.8 Hz), 129.2, 126.6 (q, *J* = 3.7 Hz), 126.2, 124.0 (q, *J* = 273.6 Hz), 123.1, 117.9; **HRMS** (ESI) *m/z*: calcd for C₁₅H₉F₃N₂NaO₂ [M+Na]⁺ 329.0508, found 329.0509.

4-(2-oxo-5-phenyl-1,3,4-oxadiazol-3(2H)-yl)benzonitrile (3f)²




Brown solid, mp 165–167 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 8.10 (d, *J* = 8.8 Hz, 2H), 7.93 – 7.91 (m, 2H), 7.73 (d, *J* = 8.8 Hz, 2H), 7.55 (dd, *J* = 18.0, 7.5 Hz, 3H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 174.8, 154.4, 150.2, 139.5, 133.5, 132.7, 129.3, 126.3, 122.9, 118.2, 109.3.

3-(4-nitrophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3g)²




Brown solid, mp 167–169 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 8.32 (d, *J* = 7.9 Hz, 2H), 8.16 (d, *J* = 7.7 Hz, 2H), 7.94 (d, *J* = 6.3 Hz, 2H), 7.56 (dd, *J* = 18.0, 6.6 Hz, 3H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 154.6, 150.2, 145.1, 141.0, 132.8, 129.4, 126.4, 125.2, 122.8, 118.0.

5-phenyl-3-(p-tolyl)-1,3,4-oxadiazol-2(3H)-one (3h)³




White solid, mp 154–156 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.91 (d, *J* = 8.2 Hz, 2H), 7.79 (d, *J* = 8.5 Hz, 2H), 7.51 – 7.46 (m, 3H), 7.24 (d, *J* = 8.6 Hz, 2H), 2.36 (s, 3H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 153.5, 150.9, 136.1, 133.8, 132.0, 129.9, 129.2, 126.1, 123.7, 118.5, 21.1.

3-(4-isopropylphenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3i)




Brown oil; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.93 (dd, *J* = 8.1, 1.4 Hz, 2H), 7.85 – 7.81 (m, 2H), 7.53 – 7.47 (m, 3H), 7.32 (d, *J* = 8.6 Hz, 2H), 2.94 (dt, *J* = 13.8, 6.9 Hz, 1H), 1.28 (s, 3H), 1.26 (s, 3H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 153.6, 151.0, 147.3, 134.0, 132.0, 129.2, 127.3, 126.1, 123.8, 118.8, 33.9, 24.1; **HRMS** (ESI) *m/z*: calcd for C₁₇H₁₆N₂NaO₂ [M+Na]⁺ 303.1104, found 303.1102.

3-(4-methoxyphenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3j)³




White solid, mp 138–140 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.92 (dd, *J* = 8.0, 1.4 Hz, 2H), 7.83 – 7.80 (m, 2H), 7.53 – 7.47 (m, 3H), 6.98 – 6.96 (m, 2H), 3.82 (s, 3H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 158.1, 153.5, 151.1, 132.0, 129.5, 129.2, 126.1, 123.8, 120.4, 114.5, 55.7.

3-(2-fluorophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3k)




Brown solid, mp 101–103 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.91 (d, *J* = 7.7 Hz, 2H), 7.59 (t, *J* = 7.7 Hz, 1H), 7.51 (dt, *J* = 14.7, 7.4 Hz, 3H), 7.42 (dd, *J* = 12.9, 7.6 Hz, 1H), 7.26 (dd, *J* = 12.3, 7.4 Hz, 2H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 156.6 (d, *J* = 253.5 Hz), 154.7, 151.7, 132.2, 130.7 (d, *J* = 7.7 Hz), 129.2, 127.1, 126.1, 124.9 (d, *J* = 3.9 Hz), 123.6, 123.1 (d, *J* = 11.6 Hz), 117.3 (d, *J* = 19.2 Hz); **HRMS** (ESI) *m/z*: calcd for C₁₄H₁₀FN₂O₂ [M+H]⁺ 257.0721, found 257.0717.

3-(2-chlorophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3l)




White solid, mp 121–123 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.91 (d, *J* = 7.6 Hz, 2H), 7.55 (s, 2H), 7.50 (dd, *J* = 13.9, 6.6 Hz, 3H), 7.43 – 7.41 (m, 2H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 154.5, 151.9, 132.6, 132.2, 132.1, 131.1, 131.0, 129.2, 129.1, 128.0, 126.1, 123.7. **HRMS** (ESI) *m/z*: calcd for C₁₄H₁₀ClN₂O₂ [M+H]⁺ 273.0425, found 273.0419.

3-(2-bromophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3m)



Brown solid, mp 123–125 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.93 (d, *J* = 7.4 Hz, 2H), 7.75 (d, *J* = 8.0 Hz, 1H), 7.51 (ddd, *J* = 20.6, 13.4, 7.7 Hz, 5H), 7.37 (t, *J* = 7.7 Hz, 1H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 154.4, 151.8, 134.2, 134.2, 132.2, 131.5, 129.5, 129.3, 128.7, 126.1, 123.7, 121.8; **HRMS** (ESI) *m/z*: calcd for C₁₄H₁₀BrN₂O₂ [M+H]⁺ 316.9920, found 316.9912.


3-(3-bromophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3n)



White solid, mp 125–127 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 8.12 (t, *J* = 1.9 Hz, 1H), 7.93 (dt, *J* = 8.4, 1.7 Hz, 3H), 7.55 – 7.48 (m, 3H), 7.39 (dd, *J* = 8.0, 1.6 Hz,


1H), 7.31 (t, J = 8.1 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃): δ (ppm) 154.0, 150.5, 137.3, 132.4, 130.7, 129.3, 129.2, 126.2, 123.3, 123.1, 121.3, 116.7; **HRMS** (ESI) m/z : calcd for C₁₄H₁₀BrN₂O₂ [M+H]⁺ 316.9920, found 316.9916.

5-phenyl-3-(m-tolyl)-1,3,4-oxadiazol-2(3H)-one (3o)




Brown solid, mp 99–101 °C; **¹H NMR** (400 MHz, CDCl₃): δ (ppm) 7.94 (dd, J = 8.1, 1.5 Hz, 2H), 7.75 (d, J = 12.0 Hz, 2H), 7.54 – 7.47 (m, 3H), 7.34 (t, J = 7.8 Hz, 1H), 7.09 (d, J = 7.6 Hz, 1H), 2.42 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ (ppm) 153.7, 150.9, 139.5, 136.2, 132.1, 129.2, 127.2, 126.2, 123.7, 119.1, 115.7, 21.8. **HRMS** (ESI) m/z : calcd for C₁₅H₁₃N₂O₂ [M+H]⁺ 253.0972, found 253.0968.

5-phenyl-3-(o-tolyl)-1,3,4-oxadiazol-2(3H)-one (3p)




Brown solid, mp 107–109 °C; **¹H NMR** (400 MHz, CDCl₃): δ (ppm) 7.91 (d, J = 6.8 Hz, 2H), 7.52 (dd, J = 10.9, 7.2 Hz, 3H), 7.43 (d, J = 7.4 Hz, 1H), 7.36 – 7.32 (m, 3H), 2.38 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ (ppm) 154.2, 152.3, 135.3, 134.0, 132.0, 131.7, 129.7, 129.2, 127.1, 126.7, 126.0, 123.9, 18.3. **HRMS** (ESI) m/z : calcd for C₁₅H₁₃N₂O₂ [M+H]⁺ 253.0972, found 253.0966.

3-(3-chloro-4-fluorophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3q)




Brown solid, mp 126–128 °C; **¹H NMR** (400 MHz, CDCl₃): δ (ppm) 8.04 (d, J = 4.1 Hz, 1H), 7.90 (dd, J = 24.2, 8.1 Hz, 3H), 7.53 (dt, J = 14.2, 6.9 Hz, 3H), 7.22 (d, J = 8.5 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃): δ (ppm) 156.2 (d, J = 247.4 Hz), 154.1, 150.5, 132.8 (d, J = 3.2 Hz), 132.5, 129.3, 126.3, 123.3, 122.0 (d, J = 18.9 Hz), 120.7, 118.0 (d, J = 7.1 Hz), 117.2 (d, J = 22.2 Hz); **HRMS** (ESI) m/z : calcd for C₁₄H₈ClFN₂NaO₂ [M+Na]⁺ 313.0151, found 313.0150.

3-(3-chloro-4-methylphenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3r)




White solid, mp 152–154 °C; **¹H NMR** (400 MHz, CDCl₃): δ (ppm) 7.60 (dd, *J* = 177.9, 75.8 Hz, 8H), 2.35 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ (ppm) 153.8, 150.5, 135.1, 134.9, 134.0, 132.2, 131.4, 129.2, 126.1, 123.4, 118.8, 116.3, 19.7; **HRMS** (ESI) *m/z*: calcd for C₁₅H₁₁ClN₂NaO₂ [M+Na]⁺ 309.0401, found 309.0403.

3-(3,5-dimethylphenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3s)




Brown oil; **¹H NMR** (400 MHz, CDCl₃): δ (ppm) 7.94 (d, *J* = 6.9 Hz, 2H), 7.56 – 7.48 (m, 5H), 6.91 (s, 1H), 2.38 (s, 6H); **¹³C NMR** (100 MHz, CDCl₃): δ (ppm) 153.6, 151.0, 139.3, 136.1, 132.1, 129.2, 128.1, 126.1, 123.7, 116.3, 21.7; **HRMS** (ESI) *m/z*: calcd for C₁₆H₁₄N₂NaO₂ [M+Na]⁺ 289.0947, found 289.0949.

5-(4-fluorophenyl)-3-phenyl-1,3,4-oxadiazol-2(3H)-one (4a)²



White solid, mp 141–143 °C; **¹H NMR** (400 MHz, CDCl₃): δ (ppm) 7.95 – 7.91 (m, 4H), 7.46 (t, *J* = 8.0 Hz, 2H), 7.29 – 7.25 (m, 1H), 7.19 (t, *J* = 8.6 Hz, 2H); **¹³C NMR** (100 MHz, CDCl₃): δ (ppm) 165.1 (d, *J* = 252.2 Hz), 153.0, 150.7, 136.2, 129.4, 128.5 (d, *J* = 8.9 Hz), 126.4, 120.0 (d, *J* = 3.2 Hz), 118.5, 116.7 (d, *J* = 8.6 Hz).


5-(4-chlorophenyl)-3-phenyl-1,3,4-oxadiazol-2(3H)-one (4b)²



White solid, mp 136–138 °C; **¹H NMR** (400 MHz, CDCl₃): δ (ppm) 7.92 (d, *J* = 8.0 Hz, 2H), 7.86 (d, *J* = 8.4 Hz, 2H), 7.46 (t, *J* = 9.4 Hz, 4H), 7.28 (t, *J* = 7.7 Hz, 1H); **¹³C**


NMR (100 MHz, CDCl₃): δ (ppm) 152.9, 150.6, 138.5, 136.1, 129.7, 129.4, 127.4, 126.5, 122.1, 118.5.

5-(4-bromophenyl)-3-phenyl-1,3,4-oxadiazol-2(3*H*)-one (4c)²




White solid, mp 124–126 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.92 (d, *J* = 8.2 Hz, 2H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.65 (d, *J* = 8.4 Hz, 2H), 7.47 (t, *J* = 7.7 Hz, 2H), 7.28 (dd, *J* = 13.5, 6.1 Hz, 1H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 153.1, 150.7, 136.2, 132.7, 129.5, 127.6, 126.9, 126.5, 122.6, 118.6.

3-phenyl-5-(p-tolyl)-1,3,4-oxadiazol-2(3*H*)-one (4d)²




White solid, mp 149–151 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.93 (d, *J* = 8.1 Hz, 2H), 7.81 (d, *J* = 8.1 Hz, 2H), 7.47 (s, 2H), 7.30 – 7.24 (m, 3H), 2.41 (s, 3H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 153.9, 150.9, 142.8, 136.3, 129.9, 129.4, 126.2, 126.1, 120.9, 118.4, 21.9.

5-(4-methoxyphenyl)-3-phenyl-1,3,4-oxadiazol-2(3*H*)-one (4e)²




White solid, mp 143–145 °C; **1H NMR** (400 MHz, CDCl₃): δ (ppm) 7.92 (d, *J* = 7.8 Hz, 2H), 7.85 (d, *J* = 8.9 Hz, 2H), 7.45 (t, *J* = 8.0 Hz, 2H), 7.25 (t, *J* = 7.4 Hz, 1H), 6.97 (d, *J* = 8.9 Hz, 2H), 3.84 (s, 3H); **13C NMR** (100 MHz, CDCl₃): δ (ppm) 162.7, 153.7, 150.9, 136.3, 129.3, 127.9, 126.1, 118.3, 116.0, 114.7, 55.6.

5-(3-chlorophenyl)-3-phenyl-1,3,4-oxadiazol-2(3*H*)-one (4f)




White solid, mp 107–109 °C; **¹H NMR** (400 MHz, CDCl₃): δ (ppm) 7.93 (d, *J* = 7.9 Hz, 3H), 7.82 (d, *J* = 7.3 Hz, 1H), 7.47 (dt, *J* = 17.5, 8.8 Hz, 4H), 7.29 (t, *J* = 7.5 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃): δ (ppm) 152.6, 150.6, 136.1, 135.5, 132.2, 130.6, 129.5, 126.6, 126.2, 125.3, 124.2, 118.5; **HRMS** (ESI) *m/z*: calcd for C₁₄H₉ClN₂NaO₂ [M+Na]⁺, 295.0245, found 295.0239.

3-phenyl-5-(m-tolyl)-1,3,4-oxadiazol-2(3H)-one (4g)²




White solid, mp 126–128 °C; **¹H NMR** (400 MHz, CDCl₃): δ (ppm) 7.93 (d, *J* = 8.1 Hz, 2H), 7.74 – 7.70 (m, 2H), 7.45 (t, *J* = 7.9 Hz, 2H), 7.38 – 7.31 (m, 2H), 7.26 (t, *J* = 6.8 Hz, 1H), 2.41 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ (ppm) 153.9, 150.9, 139.1, 136.3, 132.9, 129.4, 129.1, 126.6, 126.2, 123.5, 123.3, 118.4, 21.5.

3-phenyl-5-(o-tolyl)-1,3,4-oxadiazol-2(3H)-one (4h)²




White solid, mp 95–97 °C; **¹H NMR** (400 MHz, CDCl₃): δ (ppm) 7.95 (d, *J* = 8.3 Hz, 2H), 7.86 (d, *J* = 7.9 Hz, 1H), 7.44 (dt, *J* = 19.9, 7.5 Hz, 3H), 7.34 – 7.25 (m, 3H), 2.69 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ (ppm) 154.1, 150.6, 138.3, 136.4, 132.1, 131.6, 129.4, 128.4, 126.5, 126.2, 122.3, 118.4, 22.4.

5-(furan-2-yl)-3-phenyl-1,3,4-oxadiazol-2(3H)-one (4i)³




Brown solid, mp 106–108 °C; **¹H NMR** (400 MHz, CDCl₃): δ (ppm) 7.92 (d, *J* = 8.1 Hz, 2H), 7.65 (s, 1H), 7.46 (t, *J* = 7.9 Hz, 2H), 7.30 – 7.26 (m, 1H), 7.09 (d, *J* = 3.4 Hz, 1H), 6.61 – 6.60 (m, 1H); **¹³C NMR** (100 MHz, CDCl₃): δ (ppm) 150.0, 147.1, 146.2, 138.8, 136.1, 129.4, 126.5, 118.5, 114.7, 112.3.

3-phenyl-5-(thiophen-2-yl)-1,3,4-oxadiazol-2(3H)-one (4j)²



Brown solid, mp 134–136 °C; **¹H NMR** (400 MHz, CDCl₃): δ (ppm) 7.91 (d, *J* = 7.9 Hz, 2H), 7.68 (s, 1H), 7.55 (d, *J* = 4.6 Hz, 1H), 7.45 (t, *J* = 7.6 Hz, 2H), 7.27 (t, *J* = 6.5 Hz, 1H), 7.15 (s, 1H); **¹³C NMR** (100 MHz, CDCl₃): δ (ppm) 150.6, 150.3, 136.1, 130.4, 130.1, 129.4, 128.3, 126.4, 125.2, 118.5.

methyl 1,3-diphenyl-4,5-dihydro-1*H*-pyrazole-5-carboxylate (5a)





White solid, mp 97–99 °C; **¹H NMR** (400 MHz, CDCl₃): δ 7.67 (d, *J* = 7.0 Hz, 2H), 7.36 – 7.23 (m, 5H), 7.09 (d, *J* = 7.7 Hz, 2H), 6.85 (t, *J* = 6.9 Hz, 1H), 4.75 (dd, *J* = 12.4, 6.4 Hz, 1H), 3.69 (s, 3H), 3.62 – 3.52 (m, 1H), 3.35 (dd, *J* = 17.0, 6.3 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃): δ 172.1, 147.1, 144.7, 132.1, 129.3, 129.0, 128.7, 126.0, 119.9, 113.0, 61.7, 52.8, 38.3; **HRMS** (ESI) *m/z*: calcd for C₁₇H₁₇N₂O₂ [M+Na]⁺, 281.1285, found 281.1286.

5. Reference



- (1) W. Kuldeep, C. Yang, P. R. West, K. C. Deming, S. R. Chemburkar and R. E. Reddy, *Synth. Commun.*, 2008, **38**, 4434.
- (2) Y. Wang, X. Meng, Y.-T. Yang, L.-T. Zhang, S.-B. Guo, D. Tang, Y.-X. Li and B.-H. Chen, *Chem. Commun.*, 2015, **51**, 1905.
- (3) C.-X. Guo, W.-Z. Zhang, N. Zhang and X.-B. Lu, *J. Org. Chem.*, 2017, **82**, 7637.

6. NMR spectra



3a





3b





3c





3d





3e





3f







3g





3h





3i







3j







3k









3m





3n





3o





3p





3q





3r





3s







4a





4b





4c




4d



4e





4f



7.94
7.92
7.83
7.81


7.52
7.50
7.47
7.45
7.43
7.31
7.29
7.27





>152.58
>150.58

130.63
129.46
126.56
126.16
125.34
124.24



-118.54







4g




4h





4i




4j



7.92
7.90
7.68
7.55
7.54
7.54
7.47
7.45
7.43
7.43
7.29
7.27
7.25
7.15



150.55
<150.33
—136.11
~129.39
~126.36
—118.50



5a

